China Rush Over? Korean Firms Step Up To Seize Opportunities
Strong BIO Presence Signals Intent
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
You may also be interested in...
Latest US trade group business survey shows R&D-based pharma and medical device companies continue to see China as an important growth driver but amid unequal market access, ongoing regulatory concerns, and patchy IP protection improvements.
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.